Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.55 |
| ▸ | PPARG | P37231 | 13/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.54 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720354 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL720353 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL12581017 | 0.86 | SRR (0.42) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL14392119 | 0.85 | PPARG (0.81) | PPARAPPARGPPARDSRRPSAT1 | |
| Methylamine SCHEMBL5607639 | 0.84 | SLC7A5 (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL16451001 | 0.84 | ESR1 (0.45) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL3466702 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4451311 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4941128 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL9628212 | 0.83 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | claimed |
| WO-2025011750-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Université Toulouse III - Paul Sabatier (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| WO-2017093444-A1 | COMPOSITIONS FOR ORAL ADMINISTRATION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2017-06-08 | — | — | WO | claimed |
| WO-2017046343-A1 | COMPOSITIONS FOR RECTAL ADMINISTRATION IN THE TREATMENT OF ULCERATIVE COLITIS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2017-03-23 | — | — | WO | claimed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | claimed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | claimed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | claimed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | claimed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PPARA 1378/4885PPARG 431/4885PPARD 1337/4885 |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | PPARA 616/4885PPARG 806/4885PPARD 1245/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARA 1336/4885PPARG 467/4885PPARD 1359/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | PPARA 4/4885PPARG 3/4885PPARD 6/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARA 1378/4885PPARG 431/4885PPARD 1337/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARA 1378/4885PPARG 431/4885PPARD 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.